Evenamide for hard-to-treat schizophrenia (add-on study)
Part of Mental health clinical trials.
This trial tests a new medication, evenamide, added to your current antipsychotic treatment. It looks to see if it can help people whose schizophrenia has not responded well to standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have a confirmed diagnosis of schizophrenia that has been hard to treat with usual antipsychotic medications.
- You are currently taking at least one antipsychotic at a recommended dose.
- Your symptoms are at least moderately severe according to standard rating scales.
- You are able and willing to follow your prescribed treatment plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding NaBen (a supplement-like medicine) to clozapine can improve “residual” symptoms in adults with difficult-to-treat schizophrenia. The study also checks safety and the best dose, using a placebo (inactive pill) for comparison.
This study tests whether a new medication called aticaprant is safe and well-tolerated when added to your current antipsychotic medication for schizophrenia. The goal is to see if it could help improve symptoms without causing serious side effects.
This trial tests a combination of an NMDA-targeting medicine and an anti-inflammatory treatment for people with schizophrenia that has not responded well to several standard treatments, including clozapine. If you qualify, the goal is to see whether this combination improves symptoms more than usual care.
This trial tests an experimental combination treatment that targets two different brain receptors (sigma-1 and NMDA) to see if it can improve symptoms in people with schizophrenia that hasn't responded well to standard antipsychotics.
This trial tests whether combining an NMDA “signal-supporting” treatment with an anti-inflammatory medicine can reduce symptoms in people with schizophrenia who don’t respond well to usual antipsychotic drugs. If you’ve tried at least two antipsychotics and you’re still symptomatic, this study may be worth screening for.
This Phase 2 trial tests whether adding an “NMDA-enhancing” treatment plus an antioxidant can improve ongoing schizophrenia symptoms over 12 weeks. It’s meant for people who still have symptoms even though their usual antipsychotic dose has been stable for at least 3 months.
Hear when a new Treatment Resistant Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.